Back to Search
Start Over
Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: A retrospective study
- Source :
- Oncotarget
- Publication Year :
- 2017
- Publisher :
- Impact Journals, LLC, 2017.
-
Abstract
- // Yujin Xu 1, 2 , Xiao Zheng 1, 2 , Xue Bai 3 , Pu Li 3 , Honglian Ma 1, 2 , Jin Wang 1, 2 , Xiao Hu 1, 2 and Ming Chen 1, 2 1 Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, China 2 Zhejiang Provincial Key Laboratory of Radiation Oncology, Hangzhou, 310022, China 3 Department of Radiation Physics, Zhejiang Cancer Hospital, Hangzhou, 310022, China Correspondence to: Ming Chen, email: chenming@zjcc.org.cn Keywords: non-small cell lung cancer, integrated boost intensity-modulated radiotherapy, local control, overall survival Received: March 03, 2017 Accepted: March 31, 2017 Published: April 13, 2017 ABSTRACT Objectives: To evaluate the clinical efficacy and toxicity of simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) for patients with locally advanced non-small cell lung cancer (NSCLC). Results: All patients completed definitive radiotherapy and 74 (85.1%) patients administrated platinum-based chemotherapy. The median radiation dose was 50.4Gy to PTV and 64.4 Gy simultaneously to the PGTV. The overall response rate (ORR) was 57.5% (50/87). The median duration of follow up was 24.6 months. The 1, 2, 3-year local control rate was 79.0%, 66.1%, and 60.5%, respectively. The 1, 2, 3-year overall survival (OS) rate was 89.7%, 56.7%, and 30.6%, respectively. Subgroup analysis showed that the median OS in concurrent chemoradiation (CCRT) was much better than non-CCRT (35.7 vs. 26.4 months) (HR: 0.52, 95% CI: 0.32–0.95, P = 0.033). Twenty-two (25.3%) patients experienced acute grade 3 esophagitis and 10 (11.5%) experienced acute grade ≥ 3 radiation pneumonitis. There were 2 (2.6%) late grade 3 pulmonary toxicity and no late grade ≥ 3 esophageal toxicity was observed. Materials and Methods: A total of 87 patients with locally advanced NSCLC who received SIB-IMRT from Jan. 2009 to Dec. 2012 in our hospital were retrospectively analyzed. Male accounted for 88.5%, with a median age of 61 years old. The SIB-IMRT plans were designed to deliver 50.4–64.0 Gy in 28–33 fractions (1.8–2.1 Gy/fraction) to PTV while simultaneously delivering 60.0–74.3 Gy in 28–33 fractions (2.0–2.5 Gy/fraction) to PGTV. Conclusions: SIB-IMRT, especially with concurrent chemotherapy, appears to be an effective and safe option to treat patients with locally advanced NSCLC. More prospective clinical studies should be warranted.
- Subjects :
- Adult
Male
Oncology
China
medicine.medical_specialty
Lung Neoplasms
overall survival
medicine.medical_treatment
Subgroup analysis
030218 nuclear medicine & medical imaging
03 medical and health sciences
0302 clinical medicine
Carcinoma, Non-Small-Cell Lung
Internal medicine
medicine
Humans
Treatment Failure
Lung cancer
non-small cell lung cancer
Survival analysis
Aged
Neoplasm Staging
Retrospective Studies
Aged, 80 and over
Chemotherapy
business.industry
Cancer
Retrospective cohort study
Chemoradiotherapy
Middle Aged
medicine.disease
Combined Modality Therapy
Survival Analysis
Tumor Burden
Radiation therapy
Treatment Outcome
local control
030220 oncology & carcinogenesis
Female
Radiotherapy, Intensity-Modulated
Neoplasm Grading
Nuclear medicine
business
integrated boost intensity-modulated radiotherapy
Research Paper
Subjects
Details
- ISSN :
- 19492553
- Volume :
- 8
- Database :
- OpenAIRE
- Journal :
- Oncotarget
- Accession number :
- edsair.doi.dedup.....6ca0c1c3759781f86ae53cb4dbc9ba64